Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction

HARUHIKO YAMAZAKI, HIROYUKI IWASAKI, TOSHINARI YAMASHITA, TATSUYA YOSHIDA, NOBUYASU SUGANUMA, TAKASHI YAMANAKA, KATSUHIKO MASUDO, HIROTAKA NAKAYAMA, KAORI KOHAGURA, YASUSHI RINO and MUNETAKA MASUDA
In Vivo November 2017, 31 (6) 1225-1228;
HARUHIKO YAMAZAKI
1Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: h.yamazaki0413{at}kcch.jp
HIROYUKI IWASAKI
1Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOSHINARI YAMASHITA
1Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TATSUYA YOSHIDA
1Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NOBUYASU SUGANUMA
1Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKASHI YAMANAKA
1Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATSUHIKO MASUDO
2Department of Breast and Thyroid Surgery, Yokohama City University Medical Center Minamiku, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROTAKA NAKAYAMA
3Department of Surgery, Yokohama City University School of Medicine, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAORI KOHAGURA
3Department of Surgery, Yokohama City University School of Medicine, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUSHI RINO
3Department of Surgery, Yokohama City University School of Medicine, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MUNETAKA MASUDA
3Department of Surgery, Yokohama City University School of Medicine, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

  • Table I.
  • Table II.
  • Table III.
PreviousNext
Back to top

In this issue

In Vivo
Vol. 31, Issue 6
November-December 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
10 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction
HARUHIKO YAMAZAKI, HIROYUKI IWASAKI, TOSHINARI YAMASHITA, TATSUYA YOSHIDA, NOBUYASU SUGANUMA, TAKASHI YAMANAKA, KATSUHIKO MASUDO, HIROTAKA NAKAYAMA, KAORI KOHAGURA, YASUSHI RINO, MUNETAKA MASUDA
In Vivo Nov 2017, 31 (6) 1225-1228;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction
HARUHIKO YAMAZAKI, HIROYUKI IWASAKI, TOSHINARI YAMASHITA, TATSUYA YOSHIDA, NOBUYASU SUGANUMA, TAKASHI YAMANAKA, KATSUHIKO MASUDO, HIROTAKA NAKAYAMA, KAORI KOHAGURA, YASUSHI RINO, MUNETAKA MASUDA
In Vivo Nov 2017, 31 (6) 1225-1228;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy
  • Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma
  • The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders
  • Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma
  • Google Scholar

More in this TOC Section

  • Improved Implementation of Tumor Board Decisions: A Retrospective Single Center Observational Study in Germany
  • Delayed Primary Skin Closure Followed by Single-use Negative-pressure Wound Therapy Is Optimal for Wound Management After Bowel-stoma Reversal
  • Anamorelin in Cancer Cachexia: Gut Microbiota Effects and CONUT Score as a Predictor of Response
Show more Clinical Studies

Similar Articles

Keywords

  • Thyroid
  • nivolumab
  • immunotherapy
In Vivo

© 2025 In Vivo

Powered by HighWire